1. Interrogating and Quantifying In Vitro Cancer Drug Pharmacodynamics via Agent-Based and Bayesian Monte Carlo Modelling
- Author
-
Marios Demetriades, Marko Zivanovic, Myrianthi Hadjicharalambous, Eleftherios Ioannou, Biljana Ljujic, Ksenija Vucicevic, Zeljko Ivosevic, Aleksandar Dagovic, Nevena Milivojevic, Odysseas Kokkinos, Roman Bauer, and Vasileios Vavourakis
- Subjects
mathematical oncology ,in silico ,simulation ,Variational Bayesian Monte Carlo ,cytostatics ,drug testing ,Pharmacy and materia medica ,RS1-441 - Abstract
The effectiveness of chemotherapy in cancer cell regression is often limited by drug resistance, toxicity, and neoplasia heterogeneity. However, due to the significant complexities entailed by the many cancer growth processes, predicting the impact of interference and symmetry-breaking mechanisms is a difficult problem. To quantify and understand more about cancer drug pharmacodynamics, we combine in vitro with in silico cancer models. The anti-proliferative action of selected cytostatics is interrogated on human colorectal and breast adenocarcinoma cells, while an agent-based computational model is employed to reproduce experiments and shed light on the main therapeutic mechanisms of each chemotherapeutic agent. Multiple drug administration scenarios on each cancer cell line are simulated by varying the drug concentration, while a Bayesian-based method for model parameter optimisation is employed. Our proposed procedure of combining in vitro cancer drug screening with an in silico agent-based model successfully reproduces the impact of chemotherapeutic drugs in cancer growth behaviour, while the mechanisms of action of each drug are characterised through model-derived probabilities of cell apoptosis and division. We suggest that our approach could form the basis for the prospective generation of experimentally-derived and model-optimised pharmacological variables towards personalised cancer therapy.
- Published
- 2022
- Full Text
- View/download PDF